Adial Pharmaceuticals
ADIL
9 hedge funds and large institutions have $164K invested in Adial Pharmaceuticals in 2023 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 0 increasing their positions, 2 reducing their positions, and 13 closing their positions.
0.18% more ownership
Funds ownership: 0.01% → 0.19% (+0.18%)
55% less funds holding
Funds holding: 20 → 9 (-11)
66% less capital invested
Capital invested by funds: $488K → $164K (-$324K)
85% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 13
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$2.6K |
| 2 |
AWM
Abound Wealth Management
Franklin,
Tennessee
|
+$118 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$42.3K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$37.5K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
-$28.6K |
| 4 |
Renaissance Technologies
New York
|
-$22K |
| 5 |
State Street
Boston,
Massachusetts
|
-$10.9K |
ADIL Hedge Fund Activity: Q3 2023 in Review
9 of the 6,310 institutional investors tracked by Wall St. Rank reported a position in Adial Pharmaceuticals (ADIL) for Q3 2023, worth a combined $164K — down 66% from $488K a quarter earlier.
Sellers outnumbered buyers: 13 funds closed out of ADIL and 2 opened new positions — a net loss of 11 holders — while 2 trimmed existing stakes and 0 added.
The largest buyer was UBS Group, opening a new position worth an estimated $2.6K. The largest seller was Vanguard Group, exiting entirely with an estimated $42.3K sold.
- 9 institutional investors held Adial Pharmaceuticals (ADIL) as of Q3 2023, down from 20 in Q2 2023.
- Funds reported $164K of Adial Pharmaceuticals stock for Q3 2023, down 66% quarter-over-quarter.
- 2 funds opened new Adial Pharmaceuticals positions in Q3 2023 and 13 closed out, a net change of -11 holders.
- The largest Adial Pharmaceuticals buyer in Q3 2023 was UBS Group, an estimated $2.6K added.
- The largest Adial Pharmaceuticals seller in Q3 2023 was Vanguard Group, an estimated $42.3K sold.
Based on aggregated 13F filings for Q3 2023.